Skip to main content

Table 2 PD-L1 immunostaining in tumor and inflammatory cells and cancer phenotype

From: PD-L1 expression in tumor and inflammatory cells is associated with favorable tumor features and favorable prognosis in muscle-invasive urothelial carcinoma of the bladder not treated by immune checkpoint inhibitors

  

PD-L1 in tumor cells

  

PD-L1 in inflammatory cells

 
 

n

negative (%)

positive (%)

P

n

negative (%)

few positive (%)

many positive (%)

P

All cancers

2566

80

20

 

2566

65.9

20.7

13.4

 

pTa G2 low

452

99.1

0.9

0.0255

452

89.2

5.5

5.3

0.2181

pTa G2 high

222

96.8

3.2

 

222

83

8

8.9

 

pTa G3

148

95.9

4.1

 

148

89.2

6.1

4.7

 

pT2

437

66.6

33.4

0.0028

437

51.6

29.4

19

0.0013

pT3

582

70.3

29.7

 

582

52.9

31.1

16

 

pT4

280

78.2

21.8

 

280

65.4

23.9

10.7

 

G2

100

81

19

0.0154*

100

66

22

12

0.0768*

G3

1172

70

30

 

1171

54.4

29.2

16.4

 

pN0

634

65.6

34.4

<0.0001*

634

51.7

29.4

19

<0.0001*

pN+

425

79.3

20.7

 

425

62.1

28

9.9

 

R0

524

67.2

32.8

0.0357*

524

53.1

29.8

17.2

0.0648*

R1

128

76.6

23.4

 

128

63.8

25.2

11

 

L0

236

64.8

35.2

0.0005*

236

51.5

31.1

17.4

0.0419*

L1

255

78.8

21.2

 

255

62.7

23.9

13.3

 

V0

399

68.7

31.3

0.1539*

399

53.5

29.4

17.1

0.2662*

V1

140

75

25

 

140

61.4

24.3

14.3

 
  1. * only in pT2–4 carcinomas
  2. pT pathological stage, G Grade, pN pathological lymph node status, R resection margin status, L lymphatic vessel infiltration, V blood vessel infiltration
Back to article page

BMC Urology

ISSN: 1471-2490

Contact us